AIVITA Biomedical’s Stem Cell-Derived Retina Transplant Restores Vision Loss in Preclinical Study
IRVINE, Calif. – Oct. 29, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications,…
AIVITA Biomedical CEO Dr. Hans Keirstead to Give Keynote Address at Advanced Therapies Congress in London
IRVINE, Calif. – Oct. 4, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications,…
AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine
IRVINE, Calif. – Sept. 13, 2021 – AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative cell therapies,…
AIVITA Biomedical and University of California at Irvine Collaborators Validate 3D Printed Bioreactor for Retinal Organoid Creation
IRVINE, Calif. – Jul. 13, 2021 – AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell…
AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
IRVINE, Calif. – June 8, 2021 – AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell…
AIVITA Biomedical CEO Hans Keirstead Receives 2021 Global Humanitarian Award
IRVINE, Calif. – March 04, 2021 – AIVITA Biomedical, a private biotechnology company developing personalized vaccines for the treatment…
AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19
IRVINE, Calif. – February 25, 2021 – AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the…
AIVITA Biomedical Closes $25 Million Financing Round
IRVINE, Calif. – December 29, 2020 – AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the…
AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
IRVINE, Calif. – Nov. 17, 2020 – AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell…
AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy
IRVINE, Calif. – Nov. 2, 2020 – AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell…